Explore

AI-Enabled Tools Revolutionize Clinical Trial Feasibility, Moving it Upstream in Protocol Development

AI-Enabled Tools Revolutionize Clinical Trial Feasibility, Moving it Upstream in Protocol Development

Artificial Intelligence (AI)-enabled tools are fundamentally changing how clinical trial feasibility is conducted, shifting it from a retrospective validation step to an ongoing, iterative part of protocol development. Traditionally, feasibility studies were performed late in the process, after a protocol was largely finalized, leading to delays and costly amendments if assumptions about cohort sizes, outcome rates, or eligibility criteria proved incorrect. AI tools, such as those offered by TriNetX, now allow study teams to evaluate assumptions against real-world data (RWD) continuously as criteria are being set. This is made possible by natural language interfaces that enable users to enter eligibility criteria in plain language, which the system then translates into clinical code sets to generate patient counts instantly. For example, adjusting a single BMI exclusion criterion in a type 2 diabetes query can change the cohort size by thousands of patients in real-time, providing immediate visual feedback...

ProMIS Neurosciences Appoints Ivana Rubino as Chief Commercial Officer Amidst Ongoing Alzheimer's Drug Trial

ProMIS Neurosciences Appoints Ivana Rubino as Chief Commercial Officer Amidst Ongoing Alzheimer's Drug Trial

ProMIS Neurosciences Appoints Ivana Rubino as Chief Commercial Officer Amidst Ongoing Alzheimer's Drug Trial

Arboretum LifeSciences Launches with $30 Million Series A to Advance Precision Medicine for Common Diseases

Arboretum LifeSciences Launches with $30 Million Series A to Advance Precision Medicine for Common Diseases

Arboretum LifeSciences Launches with $30 Million Series A to Advance Precision Medicine for Common Diseases

Sensible Biotechnologies Secures $47 Million to Advance Naturally Modified mRNA Platform

Sensible Biotechnologies Secures $47 Million to Advance Naturally Modified mRNA Platform

Sensible Biotechnologies, a company focused on developing naturally modified mRNA medicines, has secured $47 million in financing. This funding includes a Series A round led by Oxford Science Enterprises and up to $20 million in non-dilutive funding from the Government of Slovakia and the European Union. The investment will support the advancement and scaling of Sensible's integrated mRNA technology, specifically its VECTOR™ platform. This platform aims to overcome limitations of conventional synthetic mRNA production by using living cells to produce naturally modified mRNA. The company's approach is designed to reduce immunogenicity, achieve high protein expression, and avoid double-stranded RNA (dsRNA) contamination, a common issue with synthetic mRNA. Sensible Biotechnologies plans to use this financing to scale up its VECTOR platform, expand its AI-enabled mRNA design and high-throughput screening capabilities, and develop clinical-grade manufacturing capabilities.

AI Transforms Clinical Trials with Enhanced Imaging Analysis and Patient Selection

AI Transforms Clinical Trials with Enhanced Imaging Analysis and Patient Selection

Artificial intelligence is revolutionizing clinical trials by significantly improving the speed, standardization, and objectivity of medical imaging analysis. Traditionally, radiologists manually review images like MRI, CT, and PET scans, a process that is time-consuming and prone to variability. AI-driven tools, utilizing deep learning and computer vision, can detect subtle changes in disease progression that are often difficult for humans to quantify. This advancement is leading to faster decision-making in drug development, with industry reports indicating AI can accelerate imaging review timelines by up to 50%. Regulatory agencies are increasingly receptive to AI in clinical trials, provided the tools are properly validated, as AI provides clear, quantifiable evidence crucial for submissions. Beyond imaging, AI is also being used to broaden clinical trial screening and is integrated into adaptive clinical trial designs. The FDA has established the Office of Innovation and Clinical Trial Modernization t...

Cleveland Clinic Hosts Second Annual London Innovation Summit to Advance Surgical Care

Cleveland Clinic Hosts Second Annual London Innovation Summit to Advance Surgical Care

Cleveland Clinic recently convened its second annual London Innovation Summit, bringing together global leaders from healthcare, academia, and industry. The summit, held near Cleveland Clinic London, focused on exploring transformative forces and key drivers shaping the future of surgical care. Discussions centered on integrating technology, data, and multidisciplinary collaboration to enhance surgical practices. Topics included advanced robotics, intelligent operating rooms, perioperative transformation, neuromodulation, bioelectronic and regenerative therapies, and strategies for commercialization and investment in surgical innovation. D. Geoffrey Vince, Ph.D., Chief, Cleveland Clinic Innovations, highlighted the rapid pace of surgical innovation, encompassing AI-enabled decision support, robotics, and bioelectronic therapies, all of which are creating new possibilities across the continuum of care. Beri Ridgeway, MD, Cleveland Clinic London President, emphasized the event's role in fostering dialogue an...

ITOCHU Strengthens Drug Development Support with AI-Driven Technologies Through MOLCURE Alliance

ITOCHU Strengthens Drug Development Support with AI-Driven Technologies Through MOLCURE Alliance

ITOCHU Strengthens Drug Development Support with AI-Driven Technologies Through MOLCURE Alliance

HHS Unveils AI Initiatives to Accelerate U.S. Clinical Trials

HHS Unveils AI Initiatives to Accelerate U.S. Clinical Trials

The U.S. Department of Health and Human Services (HHS) has announced a new program and three complementary projects aimed at significantly speeding up clinical trials through the integration of artificial intelligence (AI), advanced computational models, and real-time analysis. The core initiative, named SURPASS (Simulation-augmented, Real-time Platform Adaptive Seamless Trials), seeks to develop AI-powered platforms that will continuously and adaptively support clinical trial designs. This program includes the creation of a phaseless design engine to simulate trials for faster results with fewer patients, a continuous inference engine for real-time data analysis and trial adaptations, and an agentic AI operations layer to automate startup activities and data collection. These efforts are part of a broader strategy by HHS to transform U.S. clinical trials, building on previous initiatives like Operation TrialBlazer and the FDA's pilot program using AI for real-time clinical trial data monitoring. The goal ...

Illumina Seeks Oncology Medical Science Liaison to Advance Precision Medicine Research

Illumina Seeks Oncology Medical Science Liaison to Advance Precision Medicine Research

Illumina, a global leader in DNA and multi-omic sequencing, is actively seeking a Sr. Staff Medical Science Liaison (MSL) in Oncology. This role is crucial for advancing precision medicine research, particularly in the field of oncology. The selected individual will be responsible for demonstrating a comprehensive understanding of Illumina's product offerings, recent medical and scientific advancements, and key publications related to precision medicine in oncology. A core aspect of the position involves fostering and maintaining collaborative relationships with external scientific leaders and stakeholders. This engagement aims to facilitate scientific exchange, gather insights, and understand the evolving scientific, clinical, and research needs within the genomics community. The MSL will also manage relationships with healthcare professionals (HCPs), healthcare organizations (HCOs), professional societies, and customers across the U.S. to support scientific education and communication regarding genomic t...

Regeneron Expands Global Immunology Alliance with Sanofi, Securing $1 Billion Upfront

Regeneron Expands Global Immunology Alliance with Sanofi, Securing $1 Billion Upfront

Regeneron Expands Global Immunology Alliance with Sanofi, Securing $1 Billion Upfront

Servier Acquires Edgewise Therapeutics' Muscular Dystrophy Business to Advance Rare Neurological Disease Treatment

Servier Acquires Edgewise Therapeutics' Muscular Dystrophy Business to Advance Rare Neurological Disease Treatment

Servier, a pharmaceutical company, has completed the acquisition of Edgewise Therapeutics' muscular dystrophy business. This strategic move aims to bolster Servier's research portfolio and expertise in rare neurological diseases, with a specific focus on Becker and Duchenne muscular dystrophies. The acquisition is part of Servier's broader goal to become a global leader in this field by 2030, prioritizing genetic neurological diseases that are severely disabling. Becker muscular dystrophy is a rare, X-linked genetic disorder affecting approximately one in 18,500 live male births, leading to progressive muscle wasting. It impacts an estimated 5,000 to 6,000 male patients in the U.S. and around 35,000 people across the U.S., EU4, Japan, and China. The disease is caused by mutations in the DMD gene, which is responsible for producing dystrophin, a protein crucial for proper muscle function. Currently, there is no approved treatment to slow the progression of Becker muscular dystrophy, and management primarily...

SereNeuro Therapeutics Secures Pre-Seed Financing to Advance Non-Opioid Pain Therapies

SereNeuro Therapeutics Secures Pre-Seed Financing to Advance Non-Opioid Pain Therapies

SereNeuro Therapeutics Secures Pre-Seed Financing to Advance Non-Opioid Pain Therapies